{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T19:37:40Z","timestamp":1792870660284,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100020098","name":"IMI2","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["777492"],"award-info":[{"award-number":["777492"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003083","name":"European Association of Urology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euf.2026.08.011","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:23:48Z","timestamp":1792787028000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world Data to Assess the Applicability of Randomized Controlled Trials in Newly Metastatic Prostate Cancer"],"prefix":"10.1016","author":[{"given":"Giorgio","family":"Gandaglia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7828-6876","authenticated-orcid":false,"given":"Francesco","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Hijazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand De","family":"Meulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asieh","family":"Golozar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"de Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Nicoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Rajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan G\u00f3mez","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Steinbeisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishore Reddy","family":"Papineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracie","family":"Roggenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kotik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Victor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Evans-Axelsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"N\u2019Dow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2026.08.011_b0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"10.1016\/j.euf.2026.08.011_b0010","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.euo.2021.09.006","article-title":"Epidemiology and prevention of prostate cancer","volume":"4","author":"Gandaglia","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2026.08.011_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139440","article-title":"Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model","volume":"10","author":"Scher","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.euf.2026.08.011_b0020","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to advanced prostate cancer: AUA\/SUO guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2026.08.011_b0025","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II\u20132024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.08.011_b0030","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"Arches: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2026.08.011_b0035","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.08.011_b0040","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.08.011_b0045","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2026.08.011_b0050","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.08.011_b0055","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.08.011_b0060","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1200\/JCO.21.02517","article-title":"Orteronel for metastatic hormone-sensitive prostate cancer: a multicenter, randomized, open-label phase III trial (SWOG-1216)","volume":"40","author":"Agarwal","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2026.08.011_b0065","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.34633","article-title":"Clinical efficacy of enzalutamide vs bicalutamide combined with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a randomized clinical trial","volume":"4","author":"Vaishampayan","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euf.2026.08.011_b0070","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2026.08.011_b0075","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.08.011_b0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.08.011_b0085","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.08.011_b0090","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.euf.2026.08.011_b0095","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2026.08.011_b0100","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s13063-015-1023-4","article-title":"A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results","volume":"16","author":"Kennedy-Martin","year":"2015","journal-title":"Trials"},{"issue":"Suppl. 7","key":"10.1016\/j.euf.2026.08.011_b0105","doi-asserted-by":"crossref","first-page":"vii54","DOI":"10.1093\/rheumatology\/key109","article-title":"Randomized controlled trials and real-world data: differences and similarities to untangle literature data","volume":"57","author":"Monti","year":"2018","journal-title":"Rheumatol (Oxf Engl)"},{"key":"10.1016\/j.euf.2026.08.011_b0110","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41585-023-00748-9","article-title":"Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the Pioneer consortium","volume":"20","author":"Omar","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2026.08.011_b0115","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41585-020-0324-x","article-title":"Introducing Pioneer: a project to harness big data in prostate cancer research","volume":"17","author":"Omar","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2026.08.011_b0120","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/SP9.0000000000000024","article-title":"Research protocol for an observational health data analysis to assess the applicability of randomized controlled trials focusing on newly diagnosed metastatic prostate cancer using real-world data: Pioneer IMI\u2019s \u201cbig data for better outcomes\u201d program","volume":"28","author":"Gandaglia","year":"2024","journal-title":"Int J Surg Protoc"},{"key":"10.1016\/j.euf.2026.08.011_b0125","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1245\/s10434-024-15559-4","article-title":"Examining the concordance of patient age distribution between genitourinary (GU) clinical trials and real-world disease populations: kidney, prostate and bladder cancer analysis","volume":"31","author":"Helstrom","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.euf.2026.08.011_b0130","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.euo.2025.08.007","article-title":"Treatment trajectories in metastatic hormone-sensitive prostate cancer: a Pioneer+ big data analysis","volume":"8","author":"Nicoletti","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2026.08.011_b0135","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.euf.2025.08.005","article-title":"Observational health data analysis of the cardiovascular adverse events of systemic treatment in patients with metastatic hormone-sensitive prostate cancer: big data analytics using the Pioneer platform","volume":"11","author":"Rajwa","year":"2025","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2026.08.011_b0140","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.euros.2025.09.010","article-title":"Real-world evidence on baseline characteristics and treatment in metastatic hormone-sensitive prostate cancer: findings from the Pioneer 2.0 big data investigation group","volume":"81","author":"Rivas","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euf.2026.08.011_b0145","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/eurjpc\/zwae281","article-title":"Global burden of cardiovascular diseases: projections from 2025 to 2050","volume":"32","author":"Chong","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.euf.2026.08.011_b0150","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1053\/j.seminhematol.2008.06.006","article-title":"Epidemiology of anemia in older adults","volume":"45","author":"Patel","year":"2008","journal-title":"Semin Hematol"},{"key":"10.1016\/j.euf.2026.08.011_b0155","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","article-title":"Global, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","author":"GBD 2023 Chronic Kidney Disease Collaborators","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2026.08.011_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102404","article-title":"The influence of the introduction of PSMA-PET\/CT in Danish men diagnosed with prostate cancer","volume":"23","author":"Stroomberg","year":"2025","journal-title":"Clin Genitourin Cancer"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926001951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926001951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T19:23:09Z","timestamp":1792869789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456926001951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"alternative-id":["S2405456926001951"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2026.08.011","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world Data to Assess the Applicability of Randomized Controlled Trials in Newly Metastatic Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2026.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}